These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6346348)

  • 1. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indication of an antipsychotic action of the opiate antagonist naloxone.
    Emrich HM; Cording C; Pirée S; Kölling A; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):265-70. PubMed ID: 30101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 5. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.
    Emrich HM; Zaudig M; Kissling W; Dirlich G; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Sep; 13(5):290-8. PubMed ID: 7003611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Penfluridol. Results of a year-long clinical trial].
    Woggon B
    Int Pharmacopsychiatry; 1978; 13(1):1-15. PubMed ID: 342435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 10. Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens.
    Modestin J; Toffler G; Pia M; Greub E
    Pharmacopsychiatria; 1983 Jul; 16(4):121-6. PubMed ID: 6356177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dosage piperacetazine (Quide) in ambulatory schizophrenic patients--therapeutic efficacy and toxicity.
    Donlon PT; Rada RT
    Dis Nerv Syst; 1974 May; 35(5):231-6. PubMed ID: 17894106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High vs standard dosage fluphenazine HCL in acute schizophrenia.
    Donlon PT; Meadow A; Tupin JP; Wahba M
    J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients.
    Ramsay RA; Ban TA; Lehmann HE; Saxena BM; Bennett J
    Can Med Assoc J; 1970 May; 102(9):939-42. PubMed ID: 4157149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.
    Lotstra F; Verbanck P; Mendlewicz J; Vanderhaeghen JJ
    Biol Psychiatry; 1984 Jun; 19(6):877-82. PubMed ID: 6378259
    [No Abstract]   [Full Text] [Related]  

  • 17. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect on naloxone on schizophrenic symptoms.
    Janowsky DS; Segal DS; Bloom F; Abrams A; Guillemin R
    Am J Psychiatry; 1977 Aug; 134(8):926-7. PubMed ID: 879360
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.